Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.
Multiple Myeloma
DRUG: SPDï¼šSelinexor Oral Tablet, Pomalidomide, Dexamethasone
Progression free survival, Assessed using the updated International Myeloma Working Group Response Criteria, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
Overall survival, Assessed using the updated International Myeloma Working Group Response Criteria, From date of enrollment until date of death from any cause, assessed up to 24 months.|Overall response rate, Assessed using the updated International Myeloma Working Group Response Criteria, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.|Adverse Events, Assessed using the CTCAE criteria., From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
This is a single-arm, open-label, multicenter, exploratory study. The study plans to enroll patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.

If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events.